LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Pipeline Review, H1 2017 - Product Image

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Pipeline Review, H1 2017

  • ID: 4318738
  • Report
  • 27 pages
  • Global Markets Direct
1 of 4
LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Pipeline Review, H1 2017

Summary:

According to the recently published report 'LanC Like Protein 2 - Pipeline Review, H1 2017'; LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - LanC-like protein 2 is a protein encoded by the LANCL2 gene. It is important for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes.

The report 'LanC Like Protein 2 - Pipeline Review, H1 2017' outlays comprehensive information on the LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 8 respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Immunology and Infectious Disease which include indications Type 2 Diabetes, Inflammatory Bowel Disease, Crohn's Disease (Regional Enteritis), Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Influenza Virus Infections.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2)
  • The report reviews LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
  1. Introduction
  2. LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Overview
  3. LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Drug Profiles
  13. BT-11 - Drug Profile
  14. Product Description
  15. Mechanism Of Action
  16. R&D Progress
  17. BT-110 - Drug Profile
  18. Product Description
  19. Mechanism Of Action
  20. R&D Progress
  21. BT-12 - Drug Profile
  22. Product Description
  23. Mechanism Of Action
  24. R&D Progress
  25. BT-13 - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. BT-15 - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. BTABA-5a - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. Small Molecule to Agonize LANCL2 for Inflammatory Bowel Disease - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. Small Molecules to Agonize LANCL2 for Type II Diabetes - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Dormant Products
  46. LanC Like Protein 2 (Testis Specific Adriamycin Sensitivity Protein or G Protein Coupled Receptor 69B or GPR69B or LANCL2) - Product Development Milestones
  47. Featured News & Press Releases
  48. Jul 02, 2014: BioTherapeutics awarded National Institutes of Health; Small Business Technology Transfer program grant to advance novel therapy for Type 2 Diabetes
  49. Jun 05, 2014: European Patent issued advancing Biotherapeutics’ broad claims for treating and preventing Inflammation and Diabetes
  50. May 19, 2014: BioTherapeutics awarded National Institutes of Health Small Business Innovation Research program award to advance novel therapy for IBD
  51. Appendix
  52. Methodology
  53. Coverage
  54. Secondary Research
  55. Primary Research
  56. Expert Panel Validation
  57. Contact Us
  58. Disclaimer
List of Tables
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Stage and Route of Administration, H1
  8. Number of Products by Stage and Molecule Type, H1
  9. Dormant Projects, H1
List of Figures
  1. Number of Products under Development by Therapy Areas, H1
  2. Number of Products under Development by Indications, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll